Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
HER3-DXd + Osimertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a combination of two drugs, patritumab deruxtecan and osimertinib, to see if it is safe and effective in treating patients with lung cancer that has progressed after treatment with osimertinib. The study will also look at the preliminary antitumor activity of patritumab deruxtecan monotherapy in patients who have not responded to osimertinib.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service